Logiscreen

Aquestive Therapeutics Inc

$3.93
Market Cap 479.64M
ROE 190.9%
Gross Margin 76.0%
Debt/Equity -3.9
Current Ratio 4.1
Revenue QoQ 65.7%
EPS QoQ -0.7%
F-Score 4

About

Aquestive is pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has five commercialized products marketed by the Company and its licensees in the U.S. and around the world and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm ®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions.

Exchange
NASDAQ
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-7.33
vs median 31.50
P/B
-14.84
vs median 2.17
ROE
1.91
vs median 0.09

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics